Strategic investment · Biotech
UroGen Pharma invests $7m in IntraGel Therapeutics
The investment will advance SRGel and accelerate clinical development of TumoCure.
UroGen Pharma invested $7 million in IntraGel Therapeutics.
The funding will advance its SRGel sustained-release platform and accelerate clinical development of TumoCure, a cisplatin formulation for direct injection into solid tumors. The company describes TumoCure as Phase 2-ready, initially targeting locally advanced, inoperable head-and-neck cancer.
Use of funds
Advance SRGel platform
Accelerate clinical development of TumoCure
Funding history
Strategic investment · This round$7M